|
1
|
Awad MA, Shah A and Griffith BP: Current
status and outcomes in heart transplantation: A narrative review.
Rev Cardiovasc Med. 23:112022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hahn D, Hodson EM, Hamiwka LA, Lee VW,
Chapman JR, Craig JC and Webster AC: Target of rapamycin inhibitors
(TOR-I; sirolimus and everolimus) for primary immunosuppression in
kidney transplant recipients. Cochrane Database System Rev.
12:CD0042902019.PubMed/NCBI
|
|
3
|
Yang LS, Shan LL, Saxena A and Morris DL:
Liver transplantation: A systematic review of long-term quality of
life. Liver Int. 34:1298–1313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geissler EK: Post-transplantation
malignancies: Here today, gone tomorrow? Nat Rev Clin Oncol.
12:705–717. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dzambova M, Secnikova Z, Jirakova A,
Jůzlová K, Viklický O, Hošková L, Göpfertovà D and Hercogová J:
Malignant melanoma in organ transplant recipients: Incidence,
outcomes, and management strategies: A review of literature.
Dermatol Ther. 29:64–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park CK, Dahlke EJ, Fung K, Kitchen J,
Austin PC, Rochon PA and Chan AW: Melanoma incidence, stage, and
survival after solid organ transplant: A population-based cohort
study in Ontario, Canada. J Am Acad Dermatol. 83:754–761. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Russo I, Piaserico S, Belloni-Fortina A
and Alaibac M: Cutaneous melanoma in solid organ transplant
patients. G Ital Dermatol Venereol. 149:389–394. 2014.PubMed/NCBI
|
|
8
|
Zwald F, Carvajal RD, Walker J, Sawinski D
and Al-Adra D: Analysis of malignant melanoma risk and outcomes in
solid organ transplant recipients: Assessment of transplant
candidacy and the potential role of checkpoint inhibitors. Clin
Transplant. 35:e142642021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masuda Y, Mita A, Ohno Y, Kubota K, Notake
T, Shimizu A and Soejima Y: De novo malignancy after adult-to-adult
living donor liver transplantation: A single-center long-term
experience. Transplant Proc. 55:952–955. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang JH, Pfeiffer RM, Musgrove D,
Castenson D, Fredrickson M, Miller J, Gonsalves L, Hsieh MC, Lynch
CF, Zeng Y, et al: Cancer mortality among solid organ transplant
recipients in the United States during 1987–2018. Transplantation.
107:2433–2442. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naik MG, Arns W, Budde K, Diekmann F,
Eitner F, Gwinner W, Heyne N, Jürgensen JS, Morath C, Riester U, et
al: Sirolimus in renal transplant recipients with malignancies in
Germany. Clin Kidney J. 14:2047–2058. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kulbat A, Richter K, Stefura T,
Kołodziej-Rzepa M, Kisielewski M, Wojewoda T and Wysocki WM:
Systematic review of calcineurin inhibitors and incidence of skin
malignancies after kidney transplantation in adult patients: A
study of 309,551 cases. Curr Oncol. 30:5727–5737. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berenguer M, Burra P, Ghobrial M, Hibi T,
Metselaar H, Sapisochin G, Bhoori S, Man NK, Mas V, Ohira M, et al:
Posttransplant management of recipients undergoing liver
transplantation for hepatocellular carcinoma. Working group report
from the ILTS transplant oncology consensus conference.
Transplantation. 104:1143–1149. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim M, Rhu J, Choi GS, Kim JM and Joh JW:
Risk factors for poor survival after recurrence of hepatocellular
carcinoma after liver transplantation. Ann Surg Treat Res.
101:28–36. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rajendran L, Ivanics T, Claasen MP, Muaddi
H and Sapisochin G: The management of post-transplantation
recurrence of hepatocellular carcinoma. Clin Mol Hepatol. 28:1–16.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guba M, Graeb C, Jauch KW and Geissler EK:
Pro- and anti-cancer effects of immunosuppressive agents used in
organ transplantation. Transplantation. 77:1777–1782. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun L, Yan Y, Lv H, Li J, Wang Z, Wang K,
Wang L, Li Y, Jiang H and Zhang Y: Rapamycin targets STAT3 and
impacts c-Myc to suppress tumor growth. Cell Chem Biol.
29:373–385.e376. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rostamzadeh D, Haghshenas MR, Samadi M,
Mojtahedi Z, Babaloo Z and Ghaderi A: Immunosuppressive effects and
potent anti-tumor efficacy of mTOR inhibitor everolimus in breast
tumor-bearing mice. Iran J Allergy Asthma Immunol. 21:287–299.
2022.PubMed/NCBI
|
|
19
|
Wang Z, Han Q, Wang J, Yao W, Wang L and
Li K: Rapamycin induces autophagy and apoptosis in Kaposiform
hemangioendothelioma primary cells in vitro. J Pediatr Surg.
57:1274–1280. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu WX, Lu C, Wang B, Ren XY and Xu K:
Effects of rapamycin on osteosarcoma cell proliferation and
apoptosis by inducing autophagy. Eur Rev Med Pharmacol Sci.
24:915–921. 2020.PubMed/NCBI
|
|
21
|
Cust AE and Scolyer RA: Melanoma in
situ-getting the diagnosis and prognosis right. JAMA Dermatol.
159:699–701. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puza CJ, Cardones AR and Mosca PJ:
Examining the incidence and presentation of melanoma in the
cardiothoracic transplant population. JAMA Dermatol. 154:589–591.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bundscherer A, Hafner C, Maisch T, Becker
B, Landthaler M and Vogt T: Antiproliferative and proapoptotic
effects of rapamycin and celecoxib in malignant melanoma cell
lines. Oncol Rep. 19:547–553. 2008.PubMed/NCBI
|
|
24
|
Wang M, Xu Y, Wen GZ, Wang Q and Yuan SM:
Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma
by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.
Onco Targets Ther. 12:4643–4654. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jurisic V, Srdic-Rajic T, Konjevic G,
Bogdanovic G and Colic M: TNF-α induced apoptosis is accompanied
with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr
Biol. 239:115–122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scherbakov AM, Vorontsova SK, Khamidullina
AI, Mrdjanovic J, Andreeva OE, Bogdanov FB, Salnikova DI, Jurisic
V, Zavarzin IV and Shirinian VZ: Novel pentacyclic derivatives and
benzylidenes of the progesterone series cause anti-estrogenic and
antiproliferative effects and induce apoptosis in breast cancer
cells. Invest New Drugs. 41:142–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leary S, Underwood W and Anthony R: AVMA
guidelines for the euthanasia of animals: 2020 edition. AVMA;
Schaumburg, IL: 2020
|
|
29
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press (US); Washington, DC: 2011
|
|
30
|
Yang B and Zhao S: Polydatin regulates
proliferation, apoptosis and autophagy in multiple myeloma cells
through mTOR/p70s6k pathway. Onco Targets Ther. 10:935–944. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saber-Moghaddam N, Nomani H, Sahebkar A,
Johnston TP and Mohammadpour AH: The change of immunosuppressive
regimen from calcineurin inhibitors to mammalian target of
rapamycin (mTOR) inhibitors and its effect on malignancy following
heart transplantation. Int Immunopharmacol. 69:150–158. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gruber P and Zito PM: Skin Cancer.
StatPearls. StatPearls Publishing LLC; Treasure Island, FL:
2023
|
|
33
|
Rubatto M, Sciamarrelli N, Borriello S,
Pala V, Mastorino L, Tonella L, Ribero S and Quaglino P: Classic
and new strategies for the treatment of advanced melanoma and
non-melanoma skin cancer. Front Med (Lausanne). 9:9592892022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsai TH, Su YF, Tsai CY, Wu CH, Lee KT and
Hsu YC: RTA dh404 induces cell cycle arrest, apoptosis, and
autophagy in glioblastoma cells. Int J Mol Sci. 24:40062023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao W, Zhang L, Zhang Y, Jiang Z, Lu H,
Xie Y, Han W, Zhao W, He J, Shi Z, et al: The CDK inhibitor AT7519
inhibits human glioblastoma cell growth by inducing apoptosis,
pyroptosis and cell cycle arrest. Cell Death Dis. 14:112023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sabarwal A, Chakraborty S, Mahanta S,
Banerjee S, Balan M and Pal S: A novel combination treatment with
honokiol and rapamycin effectively restricts c-met-induced growth
of renal cancer cells, and also inhibits the expression of tumor
cell PD-L1 involved in immune escape. Cancers (Basel). 12:17822020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Z, Wang X, Cheng F, Wen X, Feng S, Yu
F, Tang H, Liu Z and Teng X: Rapamycin inhibits glioma cells growth
and promotes autophagy by miR-26a-5p/DAPK1 Axis. Cancer Manag Res.
13:2691–2700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bjedov I and Rallis C: The target of
rapamycin signalling pathway in ageing and lifespan regulation.
Genes (Basel). 11:10432020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao G, Chen W, Yan M, Liu J, Luo H, Wang C
and Yang P: Rapamycin regulates the balance between cardiomyocyte
apoptosis and autophagy in chronic heart failure by inhibiting mTOR
signaling. Int J Mol Med. 45:195–209. 2020.PubMed/NCBI
|
|
40
|
Masaki N, Aoki Y, Obara K, Kubota Y,
Bouvet M, Miyazaki J and Hoffman RM: Targeting autophagy with the
synergistic combination of chloroquine and rapamycin as a novel
effective treatment for well-differentiated liposarcoma. Cancer
Genomics Proteomics. 20:317–322. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni Z, Li H, Mu D, Hou J, Liu X, Tang S and
Zheng S: Rapamycin alleviates 2,4,6-trinitrobenzene sulfonic
acid-induced colitis through autophagy induction and NF-κB pathway
inhibition in mice. Mediators Inflamm. 2022:29232162022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ozates NP, Soğutlu F, Lerminoglu F, Demir
B, Gunduz C, Shademan B and Avci CB: Effects of rapamycin and
AZD3463 combination on apoptosis, autophagy, and cell cycle for
resistance control in breast cancer. Life Sci. 264:1186432021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kocoglu SS, Sunay FB and Akkaya PN:
Effects of monensin and rapamycin combination therapy on tumor
growth and apoptosis in a xenograft mouse model of neuroblastoma.
Antibiotics (Basel). 12:9952023. View Article : Google Scholar
|
|
44
|
Yang Z, Lei Z, Li B, Zhou Y, Zhang GM,
Feng ZH, Zhang B, Shen GX and Huang B: Rapamycin inhibits lung
metastasis of B16 melanoma cells through down-regulating alphav
integrin expression and up-regulating apoptosis signaling. Cancer
Sci. 101:494–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo JY, Teng X, Laddha SV, Ma S, Van
Nostrand SC, Yang Y, Khor S, Chan CS, Rabinowitz JD and White E:
Autophagy provides metabolic substrates to maintain energy charge
and nucleotide pools in Ras-driven lung cancer cells. Genes Dev.
30:1704–1717. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hashemi M, Paskeh MDA, Orouei S, Abbasi P,
Khorrami R, Dehghanpour A, Esmaeili N, Ghahremanzade A, Zandieh MA,
Peymani M, et al: Towards dual function of autophagy in breast
cancer: A potent regulator of tumor progression and therapy
response. Biomed Pharmacother. 161:1145462023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li J, Chen X, Kang R, Zeh H, Klionsky DJ
and Tang D: Regulation and function of autophagy in pancreatic
cancer. Autophagy. 17:3275–3296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ning B, Liu Y, Huang T and Wei Y:
Autophagy and its role in osteosarcoma. Cancer Med. 12:5676–5687.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang P and Mizushima N: LC3- and
p62-based biochemical methods for the analysis of autophagy
progression in mammalian cells. Methods. 75:13–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Z, Singh R and Aschner M: Methods
for the detection of autophagy in mammalian cells. Curr Protoc
Toxicol. 69:2012212012262016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
du Toit A, Hofmeyr JS, Gniadek TJ and Loos
B: Measuring autophagosome flux. Autophagy. 14:1060–1071.
2018.PubMed/NCBI
|
|
52
|
Klionsky DJ, Abdelmohsen K, Ab A, Abedi
MJ, Abeliovic H, Arozen AA, Adach H, Adams CM, Adams PD, Adeli K,
et al: Guidelines for the use and interpretation of assays for
monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Popova NV and Jucker M: The role of mTOR
signaling as a therapeutic target in cancer. Int J Mol Sci.
22:17432021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Burnett PE, Barrow RK, Cohen NA, Snyder SH
and Sabatini DM: RAFT1 phosphorylation of the translational
regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA.
95:1432–1437. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Choo AY, Yoon SO, Kim SG, Roux PP and
Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to
mediate cell-type-specific repression of mRNA translation. Proc
Natl Acad Sci USA. 105:17414–17419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li B, Zhou C, Yi L, Xu L and Xu M: Effect
and molecular mechanism of mTOR inhibitor rapamycin on
temozolomide-induced autophagic death of U251 glioma cells. Oncol
Lett. 15:2477–2484. 2018.PubMed/NCBI
|
